Previous 10 | Next 10 |
CHESTERBROOK, Pa., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark Demitrack, M.D., Senior Vi...
Trevena (NASDAQ: TRVN ): Q3 GAAP EPS of -$0.09 misses by $0.02 . Cash and cash equivalents of $29.23M Press Release More news on: Trevena, Inc., Earnings news and commentary, Healthcare stocks news, ,
Company expects to resubmit NDA for oliceridine in Q1 2020 Acute migraine proof-of-concept study for TRV250 initiated Company to host conference call at 8:30 a.m. EST CHESTERBROOK, Pa., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharm...
CHESTERBROOK, Pa., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) conditions, today announced four presentations at ANESTHESIOLOG...
CHESTERBROOK, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System (CNS) conditions, today announced that its management team will presen...
CHESTERBROOK, Pa., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System (CNS) conditions, today announced that its management team will part...
Trevena (NASDAQ: TRVN ) is up 3% premarket on light volume in reaction to its update on its efforts to refile a U.S. marketing application for pain med oliceridine. It received a CRL in November 2018 after a close 8-7 Ad Com vote against approval a month prior. More ...
— Completed enrollment in healthy volunteer QT study, topline data expected in Q4 2019 — — Completed characterization of inactive metabolite — — Remains on track to resubmit NDA in Q1 2020 — CHESTERBROOK, Pa., Aug. 28, 201...
Trevena, Inc. (TRVN) Q2 2019 Earnings Conference Call August 7, 2019 08:00 AM ET Company Participants Robert Yoder - Vice President and Chief Business Officer Carrie Bourdow - President and Chief Executive Officer Mark Demitrack - Chief Medical Officer Barry Shin - Chief Financ...
— Enrollment for healthy volunteer QT study ongoing, topline data on schedule for Q4 2019 readout — — Company remains on track to resubmit NDA for oliceridine in Q1 2020 — — Cash runway as of June 30, 2019 continues to sufficiently fund...
News, Short Squeeze, Breakout and More Instantly...
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile Ongoing clinical PK study with optimized formulation of TRV045 advances, with data expected 2H 2024 CHESTERBROOK, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- ...
2024-04-02 07:15:05 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for TRVN on April 2, 2024 05:40AM ET. The previous analyst recommendation was Market Outperform. TRVN was trading at $0.4 at issue of the analyst recommendation. Historical Analyst Re...
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies Company announces reduction of OLINVYK commercial support and review of alternatives for OLINVYK CHESTERBROOK, Pa., April 01, 2024 (GL...